Top 6 Total Intravenous Anesthesia (TIVA) Agents for Dogs in Canada — 2026 Guide
Total Intravenous Anesthesia (TIVA) for dogs refers to anesthetic strategies that use continuous intravenous infusion of medications to produce and maintain anesthesia without inhalant gases. In Canada, veterinarians and specialty practices increasingly favor TIVA for its precise titratability, often quicker and smoother recoveries, reduced operating-room pollution, and the ability to tailor multimodal regimens to individual patients. Clinicians and owners appreciate propofol-based infusions for predictable induction and maintenance, while adjuncts such as ketamine provide NMDA-mediated analgesia, opioids deliver potent pain control, and alpha-2 agonists offer sedation and MAC-sparing effects. Market factors that make these agents appealing include broad clinical experience, availability of multidose formulations like Alfaxan Multidose Injectable, clear dosing protocols, and a growing body of evidence supporting balanced TIVA approaches to reduce inhalant concentrations and improve perioperative comfort. For Canadian practices, supply reliability, licensed veterinary formulations, and local regulatory guidance also shape product choice and adoption.
Inception's AI took the time to understand this market in Canada · We may earn a commission on purchases. It never affects our rankings.
Top Picks Summary
Propofol Injectable Emulsion 10 mg/mL (Fresenius Kabi)
A widely used induction and maintenance TIVA agent in dogs, Fresenius Kabi's propofol offers rapid onset and predictable, short recovery times that make it a market-leading choice for procedures requiring tight control of anesthetic depth. Compared with alfaxalone and ketamine, propofol generally delivers smoother inductions and faster recoveries and—being a widely produced generic—typically carries cost and supply-chain advantages over proprietary veterinary formulations, though it provides no analgesia and may cause more cardiovascular depression than alfaxalone or ketamine-based combinations.
Alfaxan Multidose Injectable 10 mg/mL (Jurox)
Alfaxan (alfaxalone) is positioned as a veterinary-focused TIVA hypnotic that delivers reliable anesthesia with comparatively better cardiovascular stability for many canine patients, making it valuable for compromised or geriatric dogs. Compared with propofol, Alfaxan can be slightly more expensive but offers the technical advantage of preservation of blood pressure in sensitive patients and a veterinary multidose presentation, while still lacking inherent analgesia so it is often combined with opioids or ketamine for balanced TIVA.
Ketamine Hydrochloride Injection 100 mg/mL (Vetoquinol)
Ketamine is a cost-effective dissociative anesthetic and analgesic frequently used in TIVA protocols for dogs because it provides analgesia and sympathetic stimulation that help maintain cardiovascular performance during anesthesia. As a generic and economical agent, ketamine is often combined with propofol or alfaxalone to reduce hypnotic doses and add analgesia, though it may prolong recoveries and requires adjuncts (benzodiazepines, opioids) to minimize muscle rigidity and excessive excitation.
Dexdomitor 0.5 mg/mL (Zoetis)
Dexdomitor (dexmedetomidine) is a potent sedative-analgesic alpha-2 agonist that excels as a premedication to markedly reduce induction and maintenance TIVA requirements in dogs, offering reliable sedation and predictable dose-sparing effects. While it is typically more expensive than basic generics, its reversibility with atipamezole and strong anesthetic-sparing properties make it a financially and technically attractive option to cut overall anesthetic consumption compared with protocols that rely solely on hypnotics or opioids, albeit with greater bradycardia and blood pressure effects that require monitoring.
Torbugesic 10 mg/mL (Zoetis)
Torbugesic (butorphanol) is a widely used, economically efficient opioid for premedication in canine TIVA protocols that provides moderate analgesia and sedation with relatively low risk of severe respiratory depression. Compared with full mu agonists like hydromorphone, butorphanol offers a milder side-effect profile and lower regulatory burden, making it a pragmatic dose-sparing adjunct to propofol or alfaxalone, although it delivers less robust analgesia for major painful stimulation.
Hydromorphone Hydrochloride Injection 2 mg/mL (Sandoz)
Hydromorphone is a high-potency mu opioid providing superior analgesia and strong sedation that make it a go-to choice when deep analgesic support is needed within canine TIVA regimens, enabling substantial reductions in hypnotic agent doses. Compared with butorphanol and ketamine, hydromorphone delivers more predictable, intense analgesia but carries higher regulatory control, cost and a greater need for monitoring due to pronounced respiratory and cardiovascular depression—trade-offs often justified for painful or prolonged procedures.
Research and Evidence Behind Canine TIVA
A growing number of peer-reviewed veterinary studies and clinical reports support the benefits of TIVA in dogs when used with appropriate monitoring and protocols. Research highlights improved recovery quality, reduced inhalant requirements when TIVA is used as part of balanced anesthesia, and effective perioperative analgesia when opioids and NMDA antagonists are included. Pharmacokinetic and pharmacodynamic data guide infusion rates and combinations to achieve safe, effective anesthesia across patient sizes and ASA status. Safety remains dependent on vigilant monitoring of cardiovascular and respiratory parameters and on staff training in TIVA-specific dosing and emergency management.
Propofol-based infusions provide rapid onset and smooth recoveries; pharmacokinetic studies help define infusion rates for maintenance.
Ketamine, used at subanesthetic infusion doses, contributes NMDA-mediated analgesia and reduces requirements for other agents.
Alpha-2 agonists like dexmedetomidine are effective MAC-sparing sedatives but require attention to cardiovascular effects.
Opioids such as hydromorphone provide reliable analgesia and blunt nociceptive responses; multimodal approaches reduce single‑drug dosing and side effects.
Clinical and retrospective studies report fewer environmental contamination issues and lower volatile agent exposure for staff when using TIVA.
Successful TIVA depends on standard dosing protocols, infusion pumps, and continuous monitoring of oxygenation, ventilation, heart rate, and blood pressure.
Frequently Asked Questions
Which dog TIVA agent fits most procedures best?
Propofol Injectable Emulsion 10 mg/mL (Fresenius Kabi) is a widely used induction and maintenance TIVA agent in dogs, with rapid onset, short duration, and smooth, predictable infusion-based recoveries for tight control of anesthetic depth.
What exact concentration and role does Alfaxan provide?
Alfaxan Multidose Injectable 10 mg/mL (Jurox) is an alfaxalone 10 mg/mL multidose formulation licensed for canine IV induction and maintenance, and it’s described as generally preserving cardiovascular stability better for many canine patients.
How does ketamine 100 mg/mL compare for TIVA value?
Ketamine Hydrochloride Injection 100 mg/mL (Vetoquinol) is described as a cost-effective, economical component for multimodal TIVA regimens in dogs, providing NMDA antagonism, analgesia, and dissociative anesthesia often paired with sedatives/opioids.
Is ketamine better for analgesia than pure hypnosis?
Ketamine Hydrochloride Injection 100 mg/mL (Vetoquinol) is a dissociative anesthetic with NMDA antagonism and analgesia, and it’s often used with sedatives/opioids to balance anesthesia—supporting cardiovascular performance during TIVA.
Conclusion
In the Canadian 2026 clinical context, TIVA is an established and growing option for canine anesthesia that combines precision, flexibility, and often improved recovery quality. The top products featured here represent the range of agents typically used in balanced TIVA regimens: Propofol Injectable Emulsion 10 mg/mL (Fresenius Kabi), Alfaxan Multidose Injectable 10 mg/mL (Jurox), Ketamine Hydrochloride Injection 100 mg/mL (Vetoquinol), Dexdomitor 0.5 mg/mL (Zoetis), Torbugesic 10 mg/mL (Zoetis), and Hydromorphone Hydrochloride Injection 2 mg/mL (Sandoz). For most practices looking for a reliable induction and infusion foundation, Propofol Injectable Emulsion 10 mg/mL (Fresenius Kabi) is the best overall choice on this page due to its pharmacokinetic profile and widespread clinical familiarity, while Alfaxan Multidose Injectable 10 mg/mL (Jurox) is an excellent alternative where multidose convenience is a priority. We hope you found the information you were looking for; refine or expand your search using the site search to compare dosing guidelines, regulatory details, or product availability in your province.